Target
CDK2
9 abstracts
Abstract
A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.Org: Cyclacel Ltd,
Abstract
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).Org: Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Florida Cancer Specialists/Sarah Cannon Research Institute, University of Virginia, Charlottesville, VA, USA, Memorial Sloan Kettering Cancer Center,
Abstract
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).Org: Mayo Clinic, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Atlantic Health System, Carol G Simon Cancer Center, Morristown, NJ, Department of Hematology and Oncology, Mayo Clinic Florida, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Abstract
Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.Org: BioTheryX, San Diego State University Department of Biology, San Diego, CA, CanSino Biologics,
Abstract
Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.Org: Cyclacel Pharmaceuticals Inc,
Abstract
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.Org: Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Columbia University Irving Medical Center, New York, NY, USA, University of Virginia, Charlottesville, VA, USA,
Abstract
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Mission Cancer and Blood, Des Moines, IA, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Norton Cancer Institute, Louisville, KY, Perlmutter Cancer Center, NYU Langone Health, New York, NY, Dana-Farber Cancer Institute, Boston, MA, Pfizer, Inc., La Jolla, CA, Massachusetts General Hospital, Boston, MA, START Midwest, Grand Rapids, MI,
Abstract
Olutasidenib in post-venetoclax patients with mIDH1 AML.Org: Georgia Cancer Center, Augusta University, Medical College of Georgia at Augusta University, Augusta, GA, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA,
Abstract
Phase 1/2 study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors.Org: Allorion Therapeutics, Natick, MA, MaaT Pharma,